Skip to main content

Table 3 List of adverse events from Grade 1/2 and Grade 3/4 evaluated according to the NCI-CTCAE (Version 3.0) toxicity classification

From: Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

System Organ Class Adverse Event (CTCAE V3.0) - Number of pts. (%)
Grade
Grade 1/2 Grade 3/4
N % N %
Blood/Bone Marrow 16 30.2 10 18.9
Gastrointestinal 39 73.6 6 11.3
Asthenia/Fatigue 33 62.3 10 18.9
Dermatology/Skin 23 43.4 2 3.8
Metabolic/Laboratory 19 35.8 4 7.5
 Hyperglycemia  3  5.7  1  1.9
 Hyperlipidemia  11  20.8  2  3.8
Infection 12 22.6 2 3.8
Neurology 7 13.2   
Pulmonary/Upper Respiratory 6 11.3   
Renal/Genitourinary 3 5.7 1 1.9
Cardiac General 1 1.9 2 3.8
Vascular    1 1.9